Dimethyl fumarate: targeting glycolysis to treat MS

被引：20
|
作者：
Angiari, Stefano [1 ]
O'Neill, Luke A. [1 ]
机构：
[1] Trinity Coll Dublin, Sch Biochem & Immunol, Trinity Biomed Sci Inst, Dublin 2, Ireland
来源：
CELL RESEARCH | 2018年 / 28卷 / 06期
基金：
英国惠康基金;
关键词：
D O I：
10.1038/s41422-018-0045-3
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Dimethyl fumarate (DMF) is an immunomodulatory drug used in patients with multiple sclerosis (MS) and psoriasis. Kornberg and colleagues shed new light on DMF activity, demonstrating that it blocks immune cell activation through inhibition of glycolysis via post-transcriptional modification of glyceraldehyde 3-phosphate dehydrogenase (GAPDH), which confirms the pro-inflammatory role of glycolysis and points to potential new targets to treat inflammatory diseases such as MS.
引用
收藏
页码：613 / 615
页数：3
相关论文
共 50 条
  • [1] Dimethyl fumarate: targeting glycolysis to treat MS
    Stefano Angiari
    Luke A. O’Neill
    Cell Research, 2018, 28 : 613 - 615
  • [2] New Insights into Dimethyl Fumarate Mechanism of Action: Modulating Immunity By Targeting GAPDH and Aerobic Glycolysis
    Kornberg, Michael D.
    Bhargava, Pavan
    Kim, Paul M.
    Snowman, Adele
    Calabresi, Peter A.
    Snyder, Solomon H.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 36 - 37
  • [3] Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity
    Kornberg, Michael D.
    Bhargava, Pavan
    Kim, Paul M.
    Putluri, Vasanta
    Snowman, Adele M.
    Putluri, Nagireddy
    Calabresi, Peter A.
    Snyder, Solomon H.
    SCIENCE, 2018, 360 (6387) : 449 - 453
  • [4] Dimethyl fumarate reduces relapse rate in MS
    不详
    PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2011, 15 (03) : 31 - 31
  • [5] Dimethyl fumarate mediates immune modulation by inhibition of GAPDH and aerobic glycolysis
    Kornberg, Michael D.
    Bhargava, Pavan
    Calabresi, Peter
    Snyder, Solomon H.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (01) : 28 - 29
  • [6] Dimethyl Fumarate: A Review in Relapsing-Remitting MS
    Hannah A. Blair
    Drugs, 2019, 79 : 1965 - 1976
  • [7] Comparison of dimethyl fumarate and interferon outcomes in an MS cohort
    Neda Sattarnezhad
    Brian C. Healy
    Moogeh Baharnoori
    Camilo Diaz-Cruz
    James Stankiewicz
    Howard L. Weiner
    Tanuja Chitnis
    BMC Neurology, 22
  • [8] Dimethyl Fumarate: A Review in Relapsing-Remitting MS
    Emma D. Deeks
    Drugs, 2016, 76 : 243 - 254
  • [9] Adherence and tolerability to dimethyl fumarate in 253 patients with MS
    Sejbaek, T.
    Illes, Z.
    Petersen, T.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 316 - 316
  • [10] Dimethyl Fumarate: A Review in Relapsing-Remitting MS
    Blair, Hannah A.
    DRUGS, 2019, 79 (18) : 1965 - 1976
12345